Loading...
•
Dec 31, 2024
Y-mAbs Q4 2024 Earnings Report
Y-mAbs reported a 13% increase in Q4 2024 revenue, driven by growth in international sales and licensing revenue.
Key Takeaways
Y-mAbs' Q4 2024 revenue increased 13% year-over-year to $26.5 million, supported by international DANYELZA sales and a $2 million licensing payment. However, net loss widened to $6.8 million due to increased operating expenses and reduced gross profit margin. The company continues to expand its radiopharmaceutical business while strengthening the DANYELZA franchise.
Q4 2024 revenue increased 13% year-over-year to $26.5 million.
Net loss widened to $6.8 million, compared to a $1.0 million loss in Q4 2023.
International DANYELZA sales surged 78% year-over-year to $7.7 million.
Signed exclusive license agreement with Nobelpharma for DANYELZA in Japan.
Y-mAbs
Y-mAbs
Y-mAbs Revenue by Geographic Location
Revenue by Geographic Location
United States Revenue
CapyFin.com Forward Guidance
Y-mAbs expects full-year 2025 revenue to range between $75 million and $90 million, with increased investments in radiopharmaceutical development and commercial expansion.
Positive Outlook
- Projected 2025 revenue between $75M and $90M.
- Continued global expansion of DANYELZA with new licensing deals.
- Increased focus on radiopharmaceutical pipeline with ongoing clinical trials.
- Stable U.S. DANYELZA revenue despite market competition.
- Cost management efforts expected to extend cash runway into 2027.
Challenges Ahead
- Declining U.S. DANYELZA revenue due to pricing and competition.
- Increased operating costs from new business realignment strategy.
- Potential pricing pressures in international markets.
- Higher R&D spending required for radiopharmaceutical programs.
- Uncertain regulatory timelines for new pipeline products.